United Kingdom

GlaxoSmithKline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Vir Biotechnology and Gsk Start Phase 2/3 Study of Covid-19 Antibody Treatment

Lead Product(s): VIR-7831

Therapeutic Area: Infections and Infectious Diseases Product Name: GSK4182136

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Vir Biotechnology

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2020

Details:

Phase 2/3 COMET-ICE study will investigate the safety and efficacy of antibody treatment in preventing hospitalization due to COVID-19.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in all Participants in Phase I/II Trial

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial assessing single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ViiV Healthcare Reports superior efficacy of long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

Final data analysis from HPTN 083 study at AIDS 2020 shows investigational, long-acting injectable cabotegravir administered every two months is 66% more effective than daily pills in preventing HIV-1 acquisition.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Brazil, AstraZeneca Sign $127 Million Deal To Produce Experimental COVID-19 Drug

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Brazilian Health Ministry

Deal Size: $127.0 million Upfront Cash: Undisclosed

Deal Type: Partnership June 28, 2020

Details:

The AstraZeneca drug candidate is considered as the leading vaccine in the world, and most advanced in terms of development to obtain license and be used as an official medication against the virus.

Symbiosis Pharmaceutical Services LTD

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2020

Details:

Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.

Cobra Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

Cobra will provide Astrazenrca with GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

Oxford Biomedica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Vaccines Manufacturing and Innovation Centre

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 08, 2020

Details:

This five year Agreement will involve the organisations working collaboratively to enable the manufacture of viral vector based COVID-19 vaccine candidate, AZD1222, contributing towards a rapid increase in UK domestic capacity for this specialised field of vaccine manufacturing.

Oxford Biomedica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for Manufacture of COVID-19 Vaccine Candidate

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 28, 2020

Details:

As part of the Clinical & Commercial Supply Agreement, AstraZeneca will have access to Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre Oxbox, located in Oxford, UK for large scale production of COVID-19 vaccine candidate, AZD1222.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: BARDA

Deal Size: $1,000.0 million Upfront Cash: Undisclosed

Deal Type: Funding May 21, 2020

Details:

The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

GlaxoSmithKline

Vir Biotechnology and Gsk Start Phase 2/3 Study of Covid-19 Antibody Treatment

AstraZeneca PLC

COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in all Participants in Phase I/II Trial

ViiV Healthcare

ViiV Healthcare Reports superior efficacy of long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

AstraZeneca PLC

Brazil, AstraZeneca Sign $127 Million Deal To Produce Experimental COVID-19 Drug

Symbiosis Pharmaceutical Services LTD

Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture

Cobra Biologics

Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate

Oxford Biomedica

Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

Oxford Biomedica

Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for Manufacture of COVID-19 Vaccine Candidate

AstraZeneca PLC

Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine